v3.25.3
Stockholders' Equity
 9 Months Ended
Sep. 30, 2025
Equity [Abstract]  
Stockholders' Equity Stockholders’ Equity
Share-Based Compensation Expense
Share-based compensation expense for the three months ended September 30, 2025 was $16.9 million, of which $12.5 million and $4.4 million was associated with equity-classified awards and liability-classified awards, respectively. Share-based compensation expense for the nine months ended September 30, 2025 was $45.2 million, of which $34.6 million and $10.6 million was associated with equity-classified awards and liability-classified awards, respectively.
Share-based compensation expense for the three months ended September 30, 2024 was $11.8 million, of which $9.3 million and $2.5 million was associated with equity-classified awards and liability-classified awards, respectively. Share-based compensation expense for the nine months ended September 30, 2024 was $30.5 million, of which $27.2 million and $3.3 million was associated with equity-classified awards and liability-classified awards, respectively.
Restricted Stock Units
During the nine months ended September 30, 2025, the Company granted approximately 1.3 million restricted stock unit awards under the 2021 Incentive Award Plan, of which approximately 1.0 million were time-based vesting awards, the vast majority of which vest in ratable installments ranging from one to three years, and approximately 0.3 million were performance-based vesting awards granted to our executives in connection with our short-term incentive compensation
program, in each case subject to continuous employment from the grant date through the applicable vesting date unless otherwise agreed with the award recipient. We determine the grant date fair value of restricted stock unit awards by multiplying the number of restricted stock unit awards by the closing trading price of our common stock on the grant date.
Performance Stock Units
During the nine months ended September 30, 2025, the Company granted approximately 0.3 million three-year performance stock unit awards under the 2021 Incentive Award Plan, all of which were granted to our executives in connection with our long-term incentive compensation program. The performance stock unit awards are based on our Adjusted EBITDA with performance determined each year for one-third of such award but the entire award does not vest until the end of the three-year period. We determine the grant date fair value of performance stock unit awards by multiplying the number of performance stock unit awards by the closing trading price of our common stock on the grant date.
Other Share-Based Payment Awards
2025 Short-Term Incentive Program
During the nine months ended September 30, 2025, the Company adopted a short-term incentive compensation program for eligible team members who are not executive officers. Pursuant to this program, awards will be paid out in cash and/or through the issuance of fully-vested shares of the Company’s common stock in early 2026 if the Company’s performance exceeds the tranche one performance metric. As of September 30, 2025, we expect that all of these awards will be settled in fully-vested shares of the Company’s common stock. Accordingly, we are accounting for the potential issuance of these shares of common stock as share-based payment awards granted under this program. Because the incentive compensation associated with these awards represents a fixed dollar amount that, if payable, will be settled in a variable number of shares of the Company’s common stock, we are currently accounting for these awards as liability-classified share-based payment awards. Accordingly, the offset to the share-based compensation expense we have recognized in connection with these awards during the nine months ended September 30, 2025 is included in Accrued expenses and other current liabilities on our September 30, 2025 condensed consolidated balance sheet.
2024 Short-Term Incentive Program
In February 2025, our board of directors determined that our 2024 performance exceeded the tranche three performance metric under our 2024 short-term incentive compensation program and issued corresponding shares of common stock to our eligible employees. Effective as of the determination date, the $13.8 million then-outstanding liability we had recognized in connection with these liability-classified share-based payment awards was reclassified out of Accrued expenses and other current liabilities and into Common stock and Additional paid-in capital on our condensed consolidated balance sheet during the nine months ended September 30, 2025.
Accumulated Other Comprehensive Loss
Changes in the AOCL balances for the three and nine months ended September 30, 2025 were as follows (all amounts are reported net of tax):
Three Months Ended September 30, 2025Nine Months Ended September 30, 2025
Foreign Currency Translation AdjustmentsUnrealized Loss on Derivative InstrumentsTotalForeign Currency Translation AdjustmentsUnrealized Loss on Derivative InstrumentsTotal
AOCL balance at June 30, 2025 and December 31, 2024, respectively
$(8,820)$(519)$(9,339)$(12,797)$—$(12,797)
Other comprehensive (loss) income before reclassifications(1,586)718 (868)2,3911,7154,106
Amounts reclassified from AOCL to earnings— (1,674)(1,674)—(3,190)(3,190)
AOCL balance at September 30, 2025
$(10,406)$(1,475)$(11,881)$(10,406)$(1,475)$(11,881)
Changes in AOCL balances for the three and nine months ended September 30, 2024 were related to foreign currency translation adjustments only.